FOLH1 and posterior cortical atrophy: Afshar-Oromieh et al., in their seminal 2015 paper, evaluated a large yet heterogeneous cohort of PCa patients, identifying an increasing growing probability of [68Ga]Ga-PSMA-11 PET positivity with the rise in PSA levels (47.1% at PSA values below 0.2 ng/mL, 50% between 0.21 and 0.5 ng/mL, 58.3% between 0.51 and 1 ng/mL, and 71.8% between 1.1 and 2 ng/mL) [23].